Table 1.
Characteristics of IgG4-RD patients with and without malignancies (n = 602)
| Variable | Total (n = 602) | IgG4-RD with malignancies (n = 29) | IgG4-RD without malignancies (n = 573) | P value |
|---|---|---|---|---|
| Demographic data | ||||
| Agea, years | 54.6 ± 13.4 | 58.9 ± 12.1 | 54.4 ± 13.4 | 0.081 |
| Male:Female | 359:243 (1.48: 1) | 18:11 (1.64: 1) | 341:232 (1.47: 1) | 0.784 |
| Follow-up time, months | 47.0 (27.0–65.0) | 54.0 (23.0–73.0) | 46.0 (27.0–65.0) | 0.515 |
| Time from onset to diagnosis, months | 12.0 (6.0–36.0) | 24.0 (7.0–60.0) | 12.0 (6.0–36.0) | 0.052 |
| Personal history | ||||
| Smoke, n (%) | 92 (15.28%) | 6 (20.69%) | 86 (15.01%) | 0.407 |
| Alcohol, n (%) | 47 (7.81%) | 2 (6.90%) | 45 (7.85%) | 1.000 |
| Past medical history | ||||
| Allergic diseasesb | 223 (37.04%) | 14 (48.28%) | 209 (36.47%) | 0.199 |
| Cardiovascular disease, n (%) | 64 (10.63%) | 4 (13.79%) | 60 (10.47%) | 0.797 |
| Hypertension, n (%) | 150 (24.92%) | 11 (37.93%) | 139 (24.26%) | 0.097 |
| Diabetes, n (%) | 99 (16.45%) | 8 (27.59%) | 91 (15.88%) | 0.097 |
| Hyperlipidemia, n (%) | 59 (9.80%) | 3 (10.34%) | 56 (9.77%) | 1.000 |
| Laboratory results | ||||
| Complement 3 (C3), g/l | 0.897 (0.736–1.090) | 0.873 (0.762–1.100) | 0.898 (0.731–1.090) | 0.965 |
| Complement 4 (C4), g/l | 0.210 (0.155–0.273) | 0.180 (0.137–0.233) | 0.210 (0.159–0.275) | 0.135 |
| ESR, mm/h | 13.0 (7.0–34.0) | 15.0 (6.5–46.0) | 13.0 (7.0–34.0) | 0.792 |
| CRP, mg/l | 2.21 (0.91–7.28) | 2.79 (1.05–5.32) | 2.20 (0.91–7.51) | 0.789 |
| Serum globulin level, g/l | 31.60 (27.50–37.48) | 33.30 (30.80–35.33) | 31.50 (27.50–37.60) | 0.399 |
| AGR | 1.46 (1.28–1.65) | 1.15 (0.93–1.43) | 1.49 (1.29–1.65) | < 0.001** |
| Serum IgA level, g/l | 1.99 (1.35–2.79) | 1.56 (1.14–2.88) | 2.01 (1.36–2.78) | 0.235 |
| Serum IgM level, g/l | 0.84 (0.62–1.18) | 0.77 (0.62–1.34) | 0.84 (0.61–1.17) | 0.833 |
| Serum IgE level, IU/ml | 236.80 (77.89–633.25) | 320.50 (169.00–701.00) | 234.00 (73.92–625.60) | 0.172 |
| Serum IgG level, g/l | 17.42 (13.70–25.50) | 21.94 (16.30–29.80) | 17.36 (13.65–24.74) | 0.015* |
| Serum IgG4 level, mg/dl | 584.0 (273.0–1400.0) | 610.0 (444.0–2330.0) | 565.9 (269.0–1382.5) | 0.065 |
| Eosinophil count, 109/l | 0.16 (0.08–0.30) | 0.26 (0.10–0.47) | 0.16 (0.08–0.30) | 0.102 |
| Eosinophil percentage, % | 2.40 (1.00–4.50) | 6.10 (2.65–7.53) | 2.30 (1.00–4.30) | < 0.001** |
| ANA (+), n (%) | 96 (15.95%) | 4 (13.79%) | 92 (16.06%) | 0.948 |
| Elevated RF, n (%) | 80 (13.29%) | 4 (13.79%) | 76 (13.26%) | 1.000 |
| Number of involved organs | 3.0 (2.0–5.0) | 4.0 (2.0–5.0) | 3.0 (2.0–4.3) | 0.252 |
| Organ involvement | ||||
| Head and neckc | 409 (67.94%) | 22 (75.86%) | 387 (67.54%) | 0.349 |
| Aorta | 29 (4.82%) | 1 (3.45%) | 28 (4.89%) | 1.000 |
| Bile duct system | 102 (16.94%) | 6 (20.69%) | 96 (16.75%) | 0.581 |
| Endocranium | 5 (0.83%) | 0 (0) | 5 (0.87%) | 1.000 |
| Gall bladder | 76 (12.62%) | 3 (10.34%) | 73 (12.74%) | 0.926 |
| Heart and pericardium | 6 (1.00%) | 0 (0) | 6 (1.05%) | 1.000 |
| Kidney | 115 (19.10%) | 4 (13.79%) | 111 (19.37%) | 0.615 |
| Lacrimal gland | 249 (41.36%) | 15 (51.72%) | 234 (40.84%) | 0.245 |
| Liver | 28 (4.65%) | 3 (10.34%) | 25 (4.36%) | 0.298 |
| Lung | 138 (22.92%) | 8 (27.59%) | 130 (22.69%) | 0.540 |
| Lymph node | 289 (48.01%) | 18 (62.07%) | 271 (47.29%) | 0.120 |
| Mediastinum | 2 (0.33%) | 0 (0) | 2 (0.35%) | 1.000 |
| Mesentery | 11 (1.83%) | 1 (3.45%) | 10 (1.75%) | 1.000 |
| Middle ear and mastoid | 3 (0.50%) | 0 (0) | 3 (0.52%) | 1.000 |
| Orbit and peri-orbit | 58 (9.63%) | 4 (13.79%) | 54 (9.42%) | 0.649 |
| Pancreas | 167 (27.74%) | 12 (41.38%) | 155 (27.05%) | 0.093 |
| Parotid gland | 193 (32.06%) | 7 (24.14%) | 186 (32.46%) | 0.349 |
| Pituitary gland | 3 (0.50%) | 0 (0) | 3 (0.52%) | 1.000 |
| Prostate | 32 (5.32%) | 1 (3.45%) | 31 (5.41%) | 0.972 |
| Retroperitoneum | 87 (14.45%) | 4 (13.79%) | 83 (14.49%) | 1.000 |
| Sublingual gland | 19 (3.16%) | 2 (6.90%) | 17 (2.97%) | 0.524 |
| Submandibular gland | 342 (56.81%) | 20 (68.97%) | 322 (56.20%) | 0.176 |
| Thyroid | 54 (8.97%) | 0 (0) | 54 (9.42%) | 0.098 |
Values are expressed as mean ± standard deviation (SD), median (interquartile range, IQR), ratio or number (percentage)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, AGR albumin-to-globulin ratio, RF rheumatoid factor, ANA anti-nuclear antibodies
aAge, age at IgG4-related disease diagnosis
bAllergic diseases include asthma, urticaria, eczema, and allergic rhinitis
cHead and neck involvement includes orbit and peri-orbit, lacrimal gland, submandibular gland, parotid gland, sublingual gland and thyroid
*P < 0.05
**P < 0.01